Moderna’s Covid Vaccine Bolsters Immune Response in Kids Under 6

Moderna Inc. said its Covid-19 vaccine produced a strong immune response in children under age 6 in initial results from a large final-stage trial that showed modest effectiveness in reducing omicron infections. Based on the positive results and the need for Covid shots for young children, Moderna will submit the data to regulators in the U.S. and overseas as soon as possible, according to a statement. The company also said it would also apply for U.S. clearance of its vaccine in 6- to 11-year-olds, after consultation with regulators. Subscribe to our YouTube channel: Subscribe to our newest channel Quicktake Explained: Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world. To watch complete coverage on Bloomberg Quicktake 24/7, visit , or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app. Have a story to tell? Fill out this survey for a chance to have it featured on Bloomberg Quicktake: Connect with us on… YouTube: Breaking News on YouTube: Twitter: Facebook: Instagram: